Search - tctmd.com

Displaying 81 - 100 of 103

Sort: Relevancy | Date

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Daily News

FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen

Michael O'Riordan

July 16, 2018

News Daily News

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

Michael O'Riordan

April 05, 2018

News Daily News

Respiratory Syncytial Virus Linked With Cardiovascular Complications

Michael O'Riordan

April 04, 2018

News Conference News

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Michael O'Riordan

March 16, 2018

News Conference News ACC 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Michael O'Riordan

March 01, 2018

News Daily News

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Michael O'Riordan

February 20, 2018

News Daily News

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Michael O'Riordan

January 02, 2018

News Daily News

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

Michael O'Riordan

May 10, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

Advertisement

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Higher Risk of HF After ACS for Women Previously on Beta-blockers

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

Respiratory Syncytial Virus Linked With Cardiovascular Complications

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content